Denali Therapeutics (DNLI) Competitors

$19.80 +0.34 (+1.75%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$19.98 +0.18 (+0.93%)

As of 04:15 AM Eastern

DNLI vs. BEAM, RDY, ELAN, AXSM, and ARWR

Should you buy Denali Therapeutics stock or one of its competitors? MarketBeat compares Denali Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Denali Therapeutics include Beam Therapeutics (BEAM), Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Denali Therapeutics presently has a consensus target price of $34.50, suggesting a potential upside of 74.24%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 47.04%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Denali Therapeutics had 11 more articles in the media than Beam Therapeutics. MarketBeat recorded 24 mentions for Denali Therapeutics and 13 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 0.87 beat Beam Therapeutics' score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.51	-$512.54M	-$2.88	N/A
Beam Therapeutics	$139.74M	23.45	-$79.99M	-$0.68	N/A

Denali Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Denali Therapeutics beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Denali Therapeutics (NASDAQ:DNLI) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Denali Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.28% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Dr. Reddy's Laboratories	12.90%	12.28%	8.25%

Denali Therapeutics currently has a consensus target price of $34.50, suggesting a potential upside of 74.24%. Dr. Reddy's Laboratories has a consensus target price of $16.90, suggesting a potential upside of 30.35%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Denali Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Denali Therapeutics had 19 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 24 mentions for Denali Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Denali Therapeutics' average media sentiment score of 0.87 beat Dr. Reddy's Laboratories' score of -0.58 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Denali Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.51	-$512.54M	-$2.88	N/A
Dr. Reddy's Laboratories	$3.58B	3.02	$663M	$0.77	16.84

Summary

Denali Therapeutics beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Elanco Animal Health?

Denali Therapeutics (NASDAQ:DNLI) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Denali Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Denali Therapeutics had 10 more articles in the media than Elanco Animal Health. MarketBeat recorded 24 mentions for Denali Therapeutics and 14 mentions for Elanco Animal Health. Denali Therapeutics' average media sentiment score of 0.87 beat Elanco Animal Health's score of 0.54 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has higher revenue and earnings than Denali Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.51	-$512.54M	-$2.88	N/A
Elanco Animal Health	$4.72B	2.31	-$232M	-$0.50	N/A

Denali Therapeutics currently has a consensus target price of $34.50, suggesting a potential upside of 74.24%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 29.14%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Denali Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Axsome Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Denali Therapeutics presently has a consensus target price of $34.50, indicating a potential upside of 74.24%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 6.78%. Given Denali Therapeutics' higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Denali Therapeutics' return on equity of -52.20% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Denali Therapeutics had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 24 mentions for Denali Therapeutics and 21 mentions for Axsome Therapeutics. Denali Therapeutics' average media sentiment score of 0.87 beat Axsome Therapeutics' score of 0.07 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Axsome Therapeutics has higher revenue and earnings than Denali Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.51	-$512.54M	-$2.88	N/A
Axsome Therapeutics	$638.50M	18.97	-$183.17M	-$3.73	N/A

Denali Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

Denali Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Denali Therapeutics (NASDAQ:DNLI) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Arrowhead Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.51	-$512.54M	-$2.88	N/A
Arrowhead Pharmaceuticals	$829.45M	13.23	-$1.63M	-$2.15	N/A

In the previous week, Denali Therapeutics had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 24 mentions for Denali Therapeutics and 20 mentions for Arrowhead Pharmaceuticals. Denali Therapeutics' average media sentiment score of 0.87 beat Arrowhead Pharmaceuticals' score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Denali Therapeutics' return on equity of -52.20% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Denali Therapeutics currently has a consensus target price of $34.50, indicating a potential upside of 74.24%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, indicating a potential upside of 12.74%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Denali Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.09B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.29%	2.79%	5.30%
P/E Ratio	-6.87	18.52	20.99	25.65
Price / Sales	9.51	301.26	555.98	78.93
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.39	6.75	9.70	6.66
Net Income	-$512.54M	$24.11M	$3.55B	$333.63M
7 Day Performance	0.46%	-0.53%	-0.56%	-0.11%
1 Month Performance	-1.79%	0.34%	1.17%	3.94%
1 Year Performance	41.83%	78.62%	41.20%	36.07%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.3859 of 5 stars	$19.80 +1.7%	$34.50 +74.2%	+38.8%	$3.09B	$330.53M	N/A	430	Trending News Earnings Report Analyst Forecast Analyst Revision
BEAM Beam Therapeutics	3.9733 of 5 stars	$30.08 -2.0%	$49.36 +64.1%	+76.5%	$3.15B	$139.74M	N/A	510	Earnings Report Analyst Forecast
RDY Dr. Reddy's Laboratories	3.2996 of 5 stars	$13.33 -2.9%	$16.90 +26.8%	-7.9%	$11.45B	$3.81B	17.31	27,811	News Coverage Earnings Report Analyst Downgrade Gap Up
ELAN Elanco Animal Health	3.9197 of 5 stars	$22.54 +0.1%	$27.90 +23.8%	+67.2%	$11.19B	$4.72B	N/A	9,400	Analyst Downgrade
AXSM Axsome Therapeutics	2.4082 of 5 stars	$224.03 +8.5%	$235.79 +5.2%	+122.7%	$10.62B	$638.50M	N/A	380	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, RDY, ELAN, AXSM, and ARWR

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, RDY, ELAN, AXSM, and ARWR

How does Denali Therapeutics compare to Beam Therapeutics?

Do analysts recommend DNLI or BEAM?

Is DNLI or BEAM more profitable?

Does the media refer more to DNLI or BEAM?

Which has preferable valuation and earnings, DNLI or BEAM?

Which has more volatility and risk, DNLI or BEAM?

Do institutionals and insiders hold more shares of DNLI or BEAM?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Do insiders & institutionals hold more shares of DNLI or RDY?

Is DNLI or RDY more profitable?

Do analysts recommend DNLI or RDY?

Does the media prefer DNLI or RDY?

Which has more volatility & risk, DNLI or RDY?

Which has better valuation & earnings, DNLI or RDY?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Is DNLI or ELAN more profitable?

Does the media prefer DNLI or ELAN?

Which has stronger valuation and earnings, DNLI or ELAN?

Do analysts prefer DNLI or ELAN?

Which has more risk & volatility, DNLI or ELAN?

Do insiders & institutionals hold more shares of DNLI or ELAN?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Do analysts recommend DNLI or AXSM?

Do insiders and institutionals believe in DNLI or AXSM?

Is DNLI or AXSM more profitable?

Does the media refer more to DNLI or AXSM?

Which has better earnings and valuation, DNLI or AXSM?

Which has more volatility and risk, DNLI or AXSM?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Which has stronger valuation and earnings, DNLI or ARWR?

Does the media prefer DNLI or ARWR?

Is DNLI or ARWR more profitable?

Do insiders & institutionals believe in DNLI or ARWR?

Which has more risk & volatility, DNLI or ARWR?

Do analysts rate DNLI or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools